Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex31-1.htm |
| 10-K - 10-K - IMMUNE PHARMACEUTICALS INC | v434974_10k.htm |
| EX-32.1 - EXHIBIT 32.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex32-1.htm |
| EX-32.2 - EXHIBIT 32.2 - IMMUNE PHARMACEUTICALS INC | v434974_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - IMMUNE PHARMACEUTICALS INC | v434974_ex31-2.htm |
| EX-21.1 - EXHIBIT 21.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex21-1.htm |
| EX-23.2 - EXHIBIT 23.2 - IMMUNE PHARMACEUTICALS INC | v434974_ex23-2.htm |
| EX-10.44 - EXHIBIT 10.44 - IMMUNE PHARMACEUTICALS INC | v434974_ex10-44.htm |
| EX-10.45 - EXHIBIT 10.45 - IMMUNE PHARMACEUTICALS INC | v434974_ex10-45.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Immune Pharmaceuticals Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-195251) and Form S-3 (No. 333-198647) of Immune Pharmaceuticals, Inc. of our report dated March 30, 2016 relating to the financial statements of Immune Pharmaceuticals, Inc., which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
New York, New York
March 30, 2016